AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

RecruitingNAAges 9 Months - 21 YearsAllUniversity of Calgary
💬

In plain words

What the trial is, and whether it could suit you

The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: In order to be eligible to participate in this study (i.e., to be enrolled in the relevant institutional clinical care pathway), an individual must meet all of the following criteria: 1. Aged 9.0 months to \<21 years at the time of informed consent. 2. Evidence of high-risk STEC infecting pathogen defined by any of the following: 1. Bloody diarrhea within the preceding 7 days * Positive STEC culture OR * Positive antigen/polymerase chain reaction test for toxin/gene type not otherwise specified OR 2. Bloody or Non-bloody diarrhea within the preceding 7 days •Presumptive diagnosis of HUS * (meeting all 3 HUS criteria - anemia, thrombocytopenia, and renal insufficiency) OR 3. Non-bloody or no diarrhea * Positive STEC culture for high-risk strain (i.e., O103, O104, O111, O113, O121, O145 or O157) OR * Positive antigen/polymerase chain reaction test Stx2 toxin/gene Exclusion Criteria: All individuals meeting any of the exclusion criteria at baseline will be excluded from study participation. 1. Presence of Advanced HUS defined by: 1. Hematocrit \<30% AND 2. Platelet count \<150 x 103/mm3 AND 3. Creatinine \> 2.0 mg/dL (177 µmol/L) * The presence of only 1 or 2 of these criteria will not result in patient exclusion, regardless of how close the 3rd criterion is to meeting the exclusion criteria. 2. Prior episode of HUS or diagnosis of atypical HUS. 3. Chronic disease limiting fluid volumes administered (e.g. impaired renal, liver, or cardiac function, chronic lung disease). 4. Evidence of anuria (i.e., no urine output for \> 24 hours). 5. Hypoxemia requiring oxygen therapy 6. Hypertensive emergency 7. Greater than or equal to 10 days since onset of diarrhea or if no diarrhea then the onset of other symptoms. 8. Patients with known pregnancy 9. Patients or caregivers with language barriers impairing appropriate conduct of the study protocol.
💊

What it tests

  • Infusion of 200% maintenance fluids as balanced crystalloid IV solution
  • Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
📍

Where

26 sites
University of Alabama at Birmingham
Birmingham, United States
Arkansas Children's Hospital
Little Rock, United States
University of California, San Diego
La Jolla, United States
University of California, Davis
Sacramento, United States
University of Colorado Denver
Denver, United States
Children's Research Institute
Washington D.C., United States
Emory University
Atlanta, United States
Indiana University Children's Hospital
Indianapolis, United States

…and 18 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy